---
title: "CareDx Gains 2.77% on Positive AlloHeme Data"
canonical_url: https://www.stockexpertai.com/journal/2026-02-16/caredx-gains-277-on-positive-alloheme-data-2
last_updated: 2026-02-16T18:07:14.762Z
section: "Stock of the Day"
author: "Sam Rivera"
publisher: Stock Expert AI
tickers: CDNA, VVX, SYM, WM, GPN, MA
content_type: journal-article
---

# CareDx Gains 2.77% on Positive AlloHeme Data

## The Take
- CareDx's positive AlloHeme data suggests potential growth in the cell therapy market, but further research is needed to confirm its long-term impact.

_CDNA shares climb following encouraging data for AlloHeme in AML/MDS relapse detection, supporting Transplant+ expansion._

CareDx (CDNA) is in the spotlight today after reporting positive data for its AlloHeme assay. The stock is up 2.77%, trading at $19.63, driven by optimism surrounding the potential of AlloHeme in detecting early relapse in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) patients post-Hematopoietic Cell Transplantation (HCT).

The positive data seemingly validates CareDx's strategic expansion of its Transplant+ platform into the cell therapy market. AlloHeme's ability to identify minimal residual disease (MRD) earlier than conventional methods could significantly improve patient outcomes by enabling timely intervention. This is particularly crucial in AML and MDS, where early relapse detection can be the difference between successful treatment and disease progression.

CareDx is positioning AlloHeme as a key component of its comprehensive transplant solution, aiming to provide clinicians with a more complete picture of a patient's post-transplant status. The company believes this improved monitoring capability will drive adoption of its Transplant+ services and solidify its position in the growing cell therapy space. The IWM (Russell 2000 ETF) is also up today at $262.96, a gain of 1.32%.

While the market's initial reaction is positive, it's important to remember that clinical data needs to be rigorously validated through larger, more comprehensive trials. The long-term commercial success of AlloHeme will depend on its demonstrated clinical utility and cost-effectiveness. VVX is also seeing gains today, up 2.81% at $65.56.

## Related Tickers
- [CDNA](https://www.stockexpertai.com/stock/cdna)
- [VVX](https://www.stockexpertai.com/stock/vvx)
- [SYM](https://www.stockexpertai.com/stock/sym)
- [WM](https://www.stockexpertai.com/stock/wm)
- [GPN](https://www.stockexpertai.com/stock/gpn)
- [MA](https://www.stockexpertai.com/stock/ma)

## Frequently Asked Questions

### What is AlloHeme and why is it important?
AlloHeme is a diagnostic assay developed by CareDx to detect early relapse in patients who have undergone hematopoietic cell transplantation for AML and MDS. Early detection of minimal residual disease (MRD) is crucial for timely intervention and improved patient outcomes, making AlloHeme a potentially significant advancement in post-transplant monitoring.

### How is the market reacting to the AlloHeme data?
The market is reacting positively, with CareDx (CDNA) shares up 2.77% following the release of positive AlloHeme data. Investors are optimistic about the potential of AlloHeme to expand CareDx's Transplant+ platform and solidify its position in the cell therapy market.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._